Business Wire·Aug 12, 2026, 4:30 PM ET

Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results

Turn Therapeutics expanded its GX-03 Phase 2 study to include a broader atopic dermatitis population with moderate-to-severe lesions but lower overall disease extent based on interim data.
Interim analysis showed GX-03 achieved significant treatment separation across four efficacy endpoints, including 61.5% of patients reaching clear skin versus 8.3% for vehicle at Week 4.
The expanded Stage 2 trial targets enrollment of 120 to 135 patients, with study completion expected by the fourth quarter of 2026.
Dr. Stephen M. Hahn, former FDA Commissioner, was appointed Executive Clinical and Regulatory Lead to guide clinical development & regulatory strategy.
A peer-reviewed publication confirmed GX-03 significantly reduced skin inflammation in a preclinical IL-36 animal model with no treatment-related adverse effects.
The company plans to expand the GX-03 pipeline to treat Hidradenitis Suppurativa, targeting first patient dosing in the second quarter of 2027.
Turn Therapeutics reported $10.3 million in cash & cash equivalents as of June 30, 2026, providing operational runway into the third quarter of 2027.
General & administrative expenses for the quarter were $1.2 million, while research & development expenses rose to $0.5 million due to increased trial activity.
The company reported a net loss of $5.8 million for the three months ended June 30, 2026, compared to $1.2 million in the prior year period.